176 related articles for article (PubMed ID: 26176330)
41. Identification of the minimal region of peptide derived from ADP-ribosylation factor1 (ARF1) that inhibits IgE-mediated mast cell activation.
Uchida R; Egawa T; Fujita Y; Furuta K; Taguchi H; Tanaka S; Nishida K
Mol Immunol; 2019 Jan; 105():32-37. PubMed ID: 30472514
[TBL] [Abstract][Full Text] [Related]
42. IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells.
Münzberg C; Höhn K; Krndija D; Maaß U; Bartsch DK; Slater EP; Oswald F; Walther P; Seufferlein T; von Wichert G
J Cell Mol Med; 2015 May; 19(5):948-59. PubMed ID: 25754106
[TBL] [Abstract][Full Text] [Related]
43. ADP-Ribosylation factor 1 (ARF1) regulates recruitment of the AP-3 adaptor complex to membranes.
Ooi CE; Dell'Angelica EC; Bonifacino JS
J Cell Biol; 1998 Jul; 142(2):391-402. PubMed ID: 9679139
[TBL] [Abstract][Full Text] [Related]
44. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
45. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Normanno N; De Luca A; Maiello MR; Campiglio M; Napolitano M; Mancino M; Carotenuto A; Viglietto G; Menard S
J Cell Physiol; 2006 May; 207(2):420-7. PubMed ID: 16419029
[TBL] [Abstract][Full Text] [Related]
46. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
47. A homogeneous fluorescence resonance energy transfer system for monitoring the activation of a protein switch in real time.
Bill A; Blockus H; Stumpfe D; Bajorath J; Schmitz A; Famulok M
J Am Chem Soc; 2011 Jun; 133(21):8372-9. PubMed ID: 21517092
[TBL] [Abstract][Full Text] [Related]
48. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
Hwang KE; Kwon SJ; Kim YS; Park DS; Kim BR; Yoon KH; Jeong ET; Kim HR
Exp Cell Res; 2014 May; 323(2):288-96. PubMed ID: 24631288
[TBL] [Abstract][Full Text] [Related]
49. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
50. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.
Normanno N; Campiglio M; Maiello MR; De Luca A; Mancino M; Gallo M; D'Alessio A; Menard S
Breast Cancer Res Treat; 2008 Nov; 112(1):25-33. PubMed ID: 18060492
[TBL] [Abstract][Full Text] [Related]
51. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.
Kobayashi S; Ji H; Yuza Y; Meyerson M; Wong KK; Tenen DG; Halmos B
Cancer Res; 2005 Aug; 65(16):7096-101. PubMed ID: 16103058
[TBL] [Abstract][Full Text] [Related]
52. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
53. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
[TBL] [Abstract][Full Text] [Related]
54. ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR).
Xu X; Wang Q; He Y; Ding L; Zhong F; Ou Y; Shen Y; Liu H; He S
Ann Hematol; 2017 May; 96(5):847-858. PubMed ID: 28238095
[TBL] [Abstract][Full Text] [Related]
55. EGF‑stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib‑resistant human lung cancer cell line.
Nishimura Y; Takiguchi S; Ito S; Itoh K
Int J Oncol; 2015 Apr; 46(4):1721-9. PubMed ID: 25653196
[TBL] [Abstract][Full Text] [Related]
56. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
57. Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.
Wu W; O'Reilly MS; Langley RR; Tsan RZ; Baker CH; Bekele N; Tang XM; Onn A; Fidler IJ; Herbst RS
Mol Cancer Ther; 2007 Oct; 6(10):2652-63. PubMed ID: 17913856
[TBL] [Abstract][Full Text] [Related]
58. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
59. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.
Stache C; Bils C; Fahlbusch R; Flitsch J; Buchfelder M; Stefanits H; Czech T; Gaipl U; Frey B; Buslei R; Hölsken A
Neurosurg Focus; 2016 Dec; 41(6):E14. PubMed ID: 27903123
[TBL] [Abstract][Full Text] [Related]
60. Studies of the roles of ADP-ribosylation factors and phospholipase D in phorbol ester-induced membrane ruffling.
Hiroyama M; Exton JH
J Cell Physiol; 2005 Feb; 202(2):608-22. PubMed ID: 15389577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
